Richard Kim, MD, Highlights the Rationale for Assessing Pembrolizumab Plus Standard Chemo in Metastatic MSS/pMMR CRC

Video

During the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, discusses the rationale for the phase 1b KEYNOTE-651 trial examining pembrolizumab plus chemotherapy in metastatic colorectal cancer.

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, service chief of Medical Gastrointestinal Oncology and senior member in the Gastrointestinal Oncology Department at Moffitt Cancer Center in Tampa, Florida, described the rationale for the phase 1b KEYNOTE-651 trial (NCT03374254) assessing pembrolizumab (Keytruda) in combination with leucovorin and fluorouracil plus either irinotecan or oxaliplatin in microsatellite-stable (MSS) or mismatch repair (MMR) proficient metastatic colorectal cancer.

Transcript:

We know that immunotherapy is [a modality] that has been successful in other diseases. In colon cancer, unfortunately, immunotherapy only works in 5% of patients. [That] set of patients have MMR [mismatch repair] deficient, MSI [microsatellite instability] high, or POLE mutation[–positive tumors]. Therefore, the other 95% of the patient are MSS, which we call a cold tumor. The goal of the trial was to convert those cold tumors to hot tumors by adding targeted agents or chemotherapy to immunotherapy to change the microenvironment, so the immunotherapy in those situations may work better.

Reference

Kim RD, Tehfe M, Kavan P, et al. Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. J Clin Oncol. 2022;40(suppl 16):3521. doi:10.1200/JCO.2022.40.16_suppl.3521

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content